NCT05613426View on ClinicalTrials.gov

Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

PHASE4RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
ST Elevation Myocardial Infarction (STEMI)
Interventions
DRUG

Rosuvastatin 20 mg

Very early use of Rosuvastatin before primary PCI in anterior STEMI

DRUG

Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]

Very early use of Evolocumab before primary PCI in anterior STEMI

Trial Locations (6)

Unknown

RECRUITING

The People's Hospital of Gongyi, Gongyi

RECRUITING

Kaifeng Central Hospital, Kaifeng

RECRUITING

The People's Hospital of Changyuan, Xinxiang

RECRUITING

Hopeshine Minsheng Hospital of Xinzheng, Xinzheng

RECRUITING

The People's Hospital of Xuchang, Xuchang

NOT_YET_RECRUITING

Fuwai Central China Cardiovascular Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Institute of Cardiovascular Epidemiology

OTHER